Stuart Fuchs Joins Provectus Pharmaceuticals's Corporate Advisory Board - Bradenton Herald

Stuart Fuchs Joins Provectus Pharmaceuticals's Corporate consultatory Board Bradenton Herald Its dermatological drug PH-10 too targets abnormal or pathologic cells, with the actual focus on psoriasis and atopic dermatitis. Provectus has recently completed its state of matter 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a ... Alfred E. Smith 4 Appointed to Provectus Pharmaceuticals's Board of Directors MarketWatch (press release) all xxviii news articles » Link To Article